The Institute for Bioengineering of Catalonia (IBEC) has recently joined CERTERA, the State Network Consortium for the Development of Advanced Therapy Medicines. IBEC has received funding for service provision, focusing specifically on the design and execution of early-stage clinical trials.
The Institute for Bioengineering of Catalonia (IBEC) is part of the State Network Consortium for the Development of Advanced Therapy Medicines (CERTERA), which is an initiative of the Spanish Ministry of Science, Innovation and Universities, delivered through the Carlos III Health Institute (ISCIII). The consortium’s goal is to establish a collaborative scientific and technical infrastructure to accelerate the development of medicines based on advanced therapies, coordinating and structuring existing capabilities across the country.
CERTERA seeks to promote translational research, establish strategic alliances with industry, and foster an innovation ecosystem that continuously integrates new entities. The initiative is structured around three areas: drug production; expansion of production capacity; and provision of services for the development of advanced therapy medicinal products.
IBEC has received funding for service provision, focusing specifically on designing and executing early-phase clinical trials, including first-in-human trials and non-conventional trials (basket, umbrella or platform) in highly complex pathologies. This work will be carried out in collaboration with established networks such as TERAV and independent clinical research platforms such as SCReN.
The call, with a total budget of €45 million, has allocated €28.8 million to Catalonia, distributed among 12 entities. IBEC is the only Catalan research centre in the consortium, alongside universities, health institutes, and technology centres. Of the 54 applications submitted, 47 correspond to the service level.
Through this collaboration, IBEC is strengthening its commitment to cutting-edge research and clinical translation, helping to establish Catalonia as a leader in advanced therapy research.
